Methods For Drug Discovery
Immunotherapies based on targeting the PD-1:PD-L1 immune checkpoint pathway are having clinical impact and are giving new hope to cancer patients. However, positive response to treatment is not guaranteed and resistance remains a concern. Improving outcomes based on immunotherapy requires multiple approaches for manipulating the complexities of the immune system and tumor microenvironment. To meet these challenges, a series of r...
LAG3 as a Cotherapy for Immune Checkpoints
Cotherapy with PD-1
Therapeutic antibodies targeting the immune checkpoint receptors PD-1 and CTLA4 substantially changed the prognosis for many cancer patients. When successful, these treatments extend lives. Still, cancer is relentless. Only a relatively small number of patients respond or have substantial remission when these treatments are used as monotherapies.
Much of the current research on immunomodulating r...
